A Multi-center, Randomized, Open-label, Non Inferiority Trial to Evaluate the Efficacy and Safety of a Single, Oral Dose of Zoliflodacin Compared to a Combination of a Single Intramuscular Dose of Ceftriaxone and a Single Oral Dose of Azithromycin in the Treatment of Patients With Uncomplicated Gonorrhoea
Latest Information Update: 26 Apr 2024
At a glance
- Drugs Zoliflodacin (Primary) ; Azithromycin; Ceftriaxone
- Indications Gonococcal urethritis; Gonorrhoea
- Focus Registrational; Therapeutic Use
- 24 Apr 2024 Results presented in the Innoviva Media Release
- 24 Apr 2024 According to an Innoviva media release, GARDP and Innoviva Specialty Therapeutics plan to submit the Phase 3 zoliflodacin data for future publication in a medical journal.
- 24 Apr 2024 According to an Innoviva media release, data from the study will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership (GARDP) at the European Society of Clinical Microbiology and Infectious Disease Global Congress (ESCMID Global 2024) taking place April 27-30, 2024, in Barcelona, Spain.